Noah Editorial
Blog
Timely research perspectives, biotech market signals, and clinical updates in a cleaner long-form reading format.
September 22, 2026
•ComparisonBest AI Tools for Clinical Trial Eligibility Criteria Comparison (2026)
Compare AI tools for clinical trial eligibility criteria analysis, with a real Noah AI case across RASolute 305, 3082-CL-0301, and DAWN-303 in KRAS G12D metastatic pancreatic cancer.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Clinical Trial Patient Population Comparison (2026)
Compare AI tools for clinical trial patient population analysis, with a real Noah AI case across DESTINY-Breast03, Breast04, and Breast06.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Drug Class Comparison (2026)
Compare AI tools for drug class analysis, with a real Noah AI workflow comparing SGLT2 inhibitors and GLP-1 receptor agonists.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Indication Expansion Research (2026)
Compare AI tools for indication expansion research, with a real Noah AI case evaluating Enhertu from previously treated to first-line HER2-mutant NSCLC.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Medical Evidence Gap Analysis (2026)
Learn how to identify medical evidence gaps with Noah AI — separating established evidence from open questions, methodological limits, and ongoing trials — using a real 2026 TNBC pembrolizumab case.
By Linda
September 22, 2026
•Use CasesMASH Indication Strategy Report 2026: Epidemiology, Target Biology, Clinical Competition and Deal Outlook
A 2026 MASH indication strategy report covering epidemiology, fibrosis-stage opportunity, THR-beta vs FGF21, late-stage competition, deal activity and entry strategy.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Drug Safety Evidence Review (2026)
Compare the best AI tools for drug safety evidence review. We test Noah AI on T-DXd and ILD/pneumonitis to show how regulatory, trial, and real-world evidence fit together.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Drug Competitive Landscape Analysis (2026)
Compare the best AI tools for drug competitive landscape analysis, with a real 2026 U.S. obesity-drug case spanning Wegovy, Zepbound, Foundayo (orforglipron), and retatrutide.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Pipeline Asset Comparison (2026)
Compare the best AI tools for pipeline asset comparison, with a real 2026 KRAS G12D-mutated metastatic pancreatic cancer case spanning zoldonrasib, setidegrasib, and INCB161734.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Standard-of-Care Analysis (2026)
Compare the best AI tools for standard-of-care analysis in 2026, with a real U.S. first-line advanced clear-cell RCC case using guidelines, FDA labels, and pivotal clinical evidence.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Treatment Pathway Analysis (2026)
Compare the best AI tools for treatment pathway analysis, with a real 2026 U.S. EGFR-mutated advanced NSCLC pathway case spanning first-line through later-line therapy.
By Linda
September 21, 2026
•ComparisonBest AI Tools for Unmet Medical Need Analysis (2026)
Compare the best AI tools for unmet medical need analysis, with a real 2026 metastatic pancreatic cancer case accounting for the daraxonrasib (RASONQUE) FDA approval.
By Linda